Gamida Cell Presents Data on its NAM-Enabled NK Cell Therapies at Protein & Antibody Engineering Summit (PEGS) Europe
Gamida Cell (NASDAQ: GMDA) announced promising early-stage data for two NK cell therapies, GDA-501 and GDA-301, presented by Dr. Aviad Pato at the PEGS Europe conference in Barcelona, Spain, from November 2-4, 2021. GDA-501 targets HER2-overexpressing cancers, demonstrating enhanced potency against tumor cells. GDA-301, featuring CRISPR/Cas9 gene editing, showed cytotoxic activity against chronic myelogenous leukemia and multiple myeloma cell lines. This research highlights Gamida Cell's advancements in NK cell immunotherapy.
- GDA-501 shows enhanced potency against HER2-expressing tumor cells.
- GDA-301 demonstrates cytotoxic activity against leukemia and myeloma cell lines.
- Advances in NK cell immunotherapy indicated by data presented.
- None.
The presentation included data from early-stage studies of GDA-501, Gamida Cell’s investigational cell therapy comprised of CAR-engineered NK cells designed to enhance homing and activation against cancers with HER2 overexpression such as breast, ovarian, lung, bladder, and gastric cancers. Data were also presented on GDA-301, which combines a CRISPR/Cas9 knockout of the CISH (cytokine inducible SH2 containing protein) gene in NK cells with a membrane-bound IL-15/IL-15Ra CAR, which is designed to improve tumor killing by promoting activation and inhibiting negative feedback signals and has potential application in a range of solid tumors and hematologic malignancies.
Data presented by
“The field of NK cell immunotherapy is advancing beyond what has previously been understood from T cell gene editing,” said
The full presentation shared at PEGS Europe is available at www.gamida-cell.com.
About
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of initiation and progress of, and data reported from, the clinical trials of Gamida Cell’s product candidates, anticipated regulatory filings (including the submission of the BLA for omidubicel to the FDA), commercialization planning efforts, the potentially life-saving or curative therapeutic and commercial potential of omidubicel, and Gamida Cell’s expectations regarding its projected cash to be used for operating activities and cash runway. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on our business, and including the scope, progress and expansion of Gamida Cell’s clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Annual Report on Form 20-F, filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005445/en/
For investors:
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
1-212-362-1200
For media:
Ten
rhiannon@tenbridgecommunications.com
1-978-417-1946
Source:
FAQ
What did Gamida Cell present at the PEGS Europe conference?
What is GDA-501 designed to target?
What is the significance of GDA-301's CRISPR/Cas9 knockout?
When was the PEGS Europe conference held?